Abstracts Archive - Page 128 of 1683 - ATC Abstracts

2022 American Transplant Congress
Efficacy of a Multispecialty, Multidisciplinary Strategy to Improve the Level of Awareness and Control of Cardiovascular Risk Factors After Liver Transplantation
G. Crespo, L. Sastre, R. García, C. Viñals, A. J. Amor, G. Yago, A. Hervas, L. Sánchez, J. Trabal, J. Molero, L. Escude, G. Pagano, M. Blasco, R. Gilabert, P. Ruiz, J. Colmenero, M. Navasa, E. Ortega
Hospital Clinic, Barcelona, Spain
*Purpose: Although liver transplant (LT) recipients are at high cardiovascular risk, the management of cardiovascular risk factors (CVRF) after LT is far from optimal. We…
2022 American Transplant Congress
Long-Term Outcomes of Liver Transplantation (LT) Using Grafts from Donors with Active and Chronic Hepatitis B Virus (HBV) Infection; Multi-Center Cohort Study
S. Suh¹, S. Gang², Y. Choi², S. Hong², N. Yi², K. Lee², K. Suh²
¹Chung-Ang University, Seoul, Korea, Republic of, ²Seoul National University, Seoul, Korea, Republic of
*Purpose: Liver grafts from donors with hepatitis B infection contributed to expand the donor pool under the Hepatitis B immunoglobulin (HBIG) and antiviral agents (NA:…
2022 American Transplant Congress
Normothermic Machine Perfusion in Liver Transplantation – Seven Year Experience at a Single North American Centre
J. Hefler¹, D. L. Izuierdo¹, G. Meeberg², M. Bral¹, B. Anderson¹, K. Dajani¹, N. Kneteman¹, D. L. Bigam¹, A. Shapiro¹
¹Department of Surgery, University of Alberta, Edmonton, AB, Canada, ²Alberta Health Services, Edmonton, AB, Canada
*Purpose: Machine perfusion for preservation of liver grafts before transplantation has risen in prominence over the past decade. Normothermic machine perfusion (NMP), in particular, has…
2022 American Transplant Congress
Autologous Mesenchymal Stem Cells for Treatment of Chronic Antibody-Mediated Kidney Graft Rejection: Report of the First Phase I/II Clinical Case Series
Ž. Večerić-Haler¹, M. Sever², N. Kojc³, G. Mlinšek¹, M. Oblak¹, P. Halloran⁴, A. Aleš Rigler¹, J. Buturović Ponikvar¹, M. Arnol⁵
¹Nephrology, UMC Ljubljans, Ljubljana, Slovenia, ²Haematology, UMC Ljubljans, Ljubljana, Slovenia, ³Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana,, Ljubljana, Slovenia, ⁴Division of Nephrology and Transplant Immunology, University of Alberta, Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ⁵University Medical Centre Ljubljana, Ljubljana, Slovenia
*Purpose: The aim of this study is to evaluate the safety and efficacy of autologous mesenchymal stem cellc (MSCs) in combination with standard of care…
2022 American Transplant Congress
Cmv-Specific Cell-Mediated Immune Reconstitution in High-Risk Hematopoietic Cell Transplant Recipients Receiving Letermovir Prophylaxis
M. Z. Abidi¹, K. Garth¹, J. Gutman², A. Weinberg¹
¹Medicine, Infectious Disease, University of Colorado, Aurora, CO, ²Medicine, Hematology and Oncology, University of Colorado, Aurora, CO
*Purpose: In the absence of antiviral prophylaxis following Hematopoietic Cell Transplant (HCT), the incidence of clinically significant cytomegalovirus reactivation (cCMV) is 30% in CMV seropositive…
2022 American Transplant Congress
Donor Terminal Creatinine – Does It Matter?
V. G. Menon, Y. Wert, W. Hoffman, D. Ladie, M. Singh, M. Waybill, H. Yang
UPMC, Harrisburg, PA
*Purpose: When assessing deceased donor kidneys, the transplantation team studies several donor variables including creatinine. A creatinine that is elevated immediately prior to procurement can…
2022 American Transplant Congress
Living Related Kidney Donation for Alternative Complement Pathway Diseases: Long-Term Outcomes
Y. Caliskan¹, S. Safak², A. B. Dirim², A. Velioglu³, B. Yelken⁴, O. A. Oto², A. Yildiz⁵, N. Garayeva², H. Yazici², A. Ersoy⁵, A. Turkmen⁴, K. L. Lentine¹
¹Saint Louis University, Saint Louis, MO, ²Istanbul University, Istanbul, Turkey, ³Marmara University, Istanbul, Turkey, ⁴Koc University Hospital, Istanbul, Turkey, ⁵Uludag University, Bursa, Turkey
*Purpose: Atypical hemolytic-uremic syndrome (aHUS) and C3 glomerulopathy (C3G) are rare conditions that cause severe kidney disease. Data to guide the evaluation of living related…
2022 American Transplant Congress
Deletion of Fibroblastic Reticular Cell Derived Laminin A4 Impairs Lymph Node Vasculature and Conduits
L. Li¹, M. Shirkey¹, W. Piao¹, A. Kensiski¹, V. Saxena¹, T. Zhang¹, X. Li², J. Zhao², S. Gavzy¹, R. Abdi², J. Bromberg¹
¹UMB, Baltimore, MD, ²Harvard University, Boston, MA
*Purpose: Fibroblastic reticular cells (FRCs) support lymph node (LN) structure by producing various functional extracellular matrix (ECM) components. We hypothesized that FRCs and their ECM…
2022 American Transplant Congress
Outcome of Living Donor Kidney Transplant and Deceased Donor Kidney Transplant: A Retrospective Cohort Study at National Kidney and Transplant Institute
A. B. Burog, A. Parayno
ORGAN TRANSPLANTATION AND VASCULAR SURGERY, National Kidney And Transplant Institute, Quezon City, Philippines
*Purpose: To compare the graft and patient survival of living and deceased donor kidney transplant and identify the factors that affect graft survival.*Methods: Retrospective cohort…
2022 American Transplant Congress
Outcomes Following Renal Transplant with Hepatitis C Viremic Donors in an Elderly Veteran Population with Preemptive Mayvret Therapy
R. Lopez-Soler¹, A. Thorndyke¹, C. Trotter¹, A. Abadier², M. Samra¹
¹Surgery, Transplantation, Edward Hines Jr. Veterans Administration Hospital, Hines, IL, ²Surgery, Loyola University School of Medicine, Maywood, IL
*Purpose: Overall mortality on the kidney transplant waiting list is higher for older diabetic patients. The average age of waitlisted veteran patients is 64, with…